Could a simple asthma drug prevent a dangerous immunotherapy side effect?

NCT ID NCT06860542

Recruiting now Disease control Sponsor: AHS Cancer Control Alberta Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This study tests whether a year of inhaled budesonide (a common asthma medication) can prevent lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently recovered from checkpoint inhibitor pneumonitis will receive either inhaled budesonide plus standard care or standard care alone. The goal is to reduce the need for strong oral or IV steroids and improve quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE-RELATED ADVERSE EVENT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Arthur J.E. Child Comprehensive Cancer Centre
RECRUITING

Calgary, Alberta, T2N 5G2, Canada

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.